Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inﬂammatory bowel disease in tertiary center

The aim of this study was to evaluate the prevalence and risk factors related to metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients. This is a cross-sectional study conducted on adults with inflammatory bowel disease from 2019 to 2021. Metabolic dysfuncti...

Full description

Saved in:

Bibliographic Details
Published in:	Revista da Associacao Medica Brasileira (1992) Vol. 70; no. 6; p. e20231321
Main Authors:	Oliveira, Lívia Dos Remédios Pamplona de, Ribeiro, Tarsila Campanha da Rocha, Mourao Junior, Carlos Alberto, Barra, Maria Antônia de Lima, Silva, Mariana Hippert Gonçalves, Shafee, Luis Pordeus, Zacarias, Sarah Mendes, Campos, Lenilton da Costa, Valério, Helena Maria Giordano, Chebli, Júlio Maria Fonseca
Format:	Magazine Article
Language:	English
Published:	Brazil Associação Médica Brasileira 01-01-2024
Subjects:	Adult Body Mass Index Brazil - epidemiology Cross-Sectional Studies Fatty Liver - complications Fatty Liver - epidemiology Female Humans Inflammatory Bowel Diseases - complications Inflammatory Bowel Diseases - epidemiology Male Metabolic Syndrome - complications Metabolic Syndrome - epidemiology Middle Aged Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - epidemiology Original Prevalence Risk Factors Tertiary Care Centers Brazil
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The aim of this study was to evaluate the prevalence and risk factors related to metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients. This is a cross-sectional study conducted on adults with inflammatory bowel disease from 2019 to 2021. Metabolic dysfunction-associated steatotic liver disease encompasses patients with steatosis and at least one cardiometabolic risk factor. Patients with alcohol consumption ≥20 g/day, chronic liver diseases, or methotrexate use were excluded. Almost 140 patients were included: 67.1% were female, with a mean age of 49.7±13.7 years, and 63.6% had Crohn's disease. The mean duration of inflammatory bowel disease was 9.7±7.9 years. Metabolic dysfunction-associated steatotic liver disease was observed in 44.3% and advanced liver fibrosis was excluded in 63.5% by Fibrosis-4. Patients with metabolic dysfunction-associated steatotic liver disease were older (p = 0.003) and had a higher number of metabolic syndrome components (2.9±1.1 versus 1.6±1.0; p<0.001), greater abdominal circumference (p<0.001), and body mass index (p<0.001). The only factor related to inflammatory bowel disease associated with metabolic dysfunction-associated steatotic liver disease was disease duration (11.6±9.5 versus 8.3±6.2; p = 0.017). A higher number of metabolic syndrome components and obesity increase by 2.2 times and an altered waist circumference by 2.6 times the occurrence of metabolic dysfunction-associated steatotic liver disease. A high prevalence of metabolic dysfunction-associated steatotic liver disease was observed in patients with inflammatory bowel disease, with the main risk factors being associated with metabolic syndrome predicting it, but not with inflammatory bowel disease features and/or its treatment.
Bibliography:	Conflicts of interest: the authors declare there is no conflicts of interest.
ISSN:	0104-4230 1806-9282
DOI:	10.1590/1806-9282.20231321